

# Protocol for the donation of samples by volunteers for laboratory research

<b>Submission date</b> 02/02/2023	<b>Recruitment status</b> Recruiting	<input type="checkbox"/> Prospectively registered
		<input type="checkbox"/> Protocol
<b>Registration date</b> 03/02/2023	<b>Overall study status</b> Ongoing	<input type="checkbox"/> Statistical analysis plan
		<input type="checkbox"/> Results
<b>Last Edited</b> 18/04/2024	<b>Condition category</b> Other	<input type="checkbox"/> Individual participant data
		<input type="checkbox"/> Record updated in last year

## Plain English summary of protocol

### Background and study aims

This study aims to obtain blood and/or urine, stool, skin, sputum, saliva, mucosal or nasal samples from healthy volunteers and patient volunteers for laboratory research, relating to the causes and treatment of disease, in order to identify markers of disease and drug effect or development of new laboratory methods.

### Who can participate?

Men and women 18 years old or over

### What does the study involve?

This study will involve ad hoc visits to the Medicines Evaluation Unit. After written informed consent is obtained, participants will be assessed for their eligibility to donate the samples required according to the specific procedure to be undertaken. Participants have one or more of the following samples taken at a single visit: sputum, blood, urine, nasal, stool or skin.

### What are the possible benefits and risks of participating?

All sampling procedures are considered safe. There is a small risk of side effects such as bruising, bleeding and infection. This is laboratory research so there is no direct benefit to the participant.

### Where is the study run from?

Medicines Evaluation Unit (UK)

### When is the study starting and how long is it expected to run for?

November 2009 to December 2030

### Who is funding the study?

Investigator initiated and funded

### Who is the main contact?

Clinical Research Leader

## Contact information

**Type(s)**

Public

**Contact name**

Miss Natalie Jackson

**Contact details**

MEU

The Langley Building

Southmoor Road

Manchester

United Kingdom

M23 9QZ

+44 (0)1619464065

njackson@meu.org.uk

**Type(s)**

Scientific

**Contact name**

Miss Natalie Jackson

**Contact details**

MEU

The Langley Building

Southmoor Road

Manchester

United Kingdom

M23 9QZ

+44 (0)1619464065

njackson@meu.org.uk

**Type(s)**

Principal investigator

**Contact name**

Prof Dave Singh

**Contact details**

MEU

The Langley Building

Southmoor Road

Manchester

United Kingdom

M23 9QZ

+44 (0)1619464073

dsingh@meu.org.uk

**Additional identifiers**

## **Clinical Trials Information System (CTIS)**

Nil known

## **Integrated Research Application System (IRAS)**

149078

### **Protocol serial number**

DS-10-01, IRAS 149078, 46616

## **Study information**

### **Scientific Title**

Protocol for the donation of blood, urine, stool, dermatological, sputum and nasal samples by healthy volunteers and patient volunteers for laboratory research

### **Study objectives**

Identifying markers of disease and developing new assays

### **Ethics approval required**

Old ethics approval format

### **Ethics approval(s)**

Approved 12/04/2010, North West Preston Research Ethics Committee (HRA Centre Manchester, Barlow House, 3rd Floor, 4 Minshull Street, Manchester M1 3DZ, UK; +44 (0) 2071048290; preston.rec@hra.nhs.uk), ref: 10/H1016/25

### **Study design**

Observational cross sectional study

### **Primary study design**

Observational

### **Study type(s)**

Diagnostic

### **Health condition(s) or problem(s) studied**

Healthy volunteers and patient volunteers of all conditions

### **Interventions**

Participants have one or more of the following samples taken at a single visit: sputum, blood, urine, nasal, stool or skin.

### **Intervention Type**

Other

### **Primary outcome(s)**

Sputum eosinophil counts in stable state measured using cytology at a single timepoint

### **Key secondary outcome(s)**

Sputum supernatant cytokines including IL-8 and TNF- $\alpha$  in stable state measured using immunoassay at a single timepoint

**Completion date**

31/12/2030

**Eligibility**

**Key inclusion criteria**

1. Able to give written informed consent
2. Males and females aged over 18 years
3. Procedure specific criteria

**Participant type(s)**

Mixed

**Healthy volunteers allowed**

No

**Age group**

Adult

**Lower age limit**

18 years

**Sex**

All

**Key exclusion criteria**

1. History of anaemia or identified by haemocue test at screening or other clinically significant haematological disorders for blood donation
2. Current acute illness
3. Pregnancy or breastfeeding
4. History of Hepatitis B/C or HIV infection or a positive test at screen if required by the specific project
5. Volunteers who have donated to the blood transfusion service in the past 4 months, if applicable (applicable for blood donation or if specified for other procedures as per project-specific exclusion criteria)
6. Suspected use of drugs of abuse or positive drug screen, if required
7. Any contraindications for nasal sampling e.g. history of epistaxis, nasal defects, as assessed by the physician
8. Procedure-specific criteria and contraindications for performing the specific procedure
9. Any reason that the physician deems the subject not suitable to undertake the procedure(s)

**Date of first enrolment**

07/05/2010

**Date of final enrolment**

31/12/2029

## Locations

### Countries of recruitment

United Kingdom

England

### Study participating centre

#### Medicines Evaluation Unit Limited

The Langley Building

Southmoor Road

Wythenshawe

Manchester

United Kingdom

M23 9QZ

## Sponsor information

### Organisation

Medicines Evaluation Unit

### ROR

<https://ror.org/05e497m36>

## Funder(s)

### Funder type

Other

### Funder Name

Investigator initiated and funded

## Results and Publications

### Individual participant data (IPD) sharing plan

The datasets generated during and/or analysed during the current study are not expected to be made available due to the exploratory nature of the research and assays.

### IPD sharing plan summary

Not expected to be made available

